Form 4: Ezra Friedberg Sells Pelthos Therapeutics Stock

Director Ezra Friedberg of Pelthos Therapeutics Inc. reported the sale of 534 shares of common stock on July 2, 2026, for an aggregate price of $26.0303 per share, as part of a pre-arranged 10b5-1 plan.

Summary

• Director Ezra Friedberg of Pelthos Therapeutics Inc. (PTHS) reported a sale of 534 shares of common stock on July 2, 2026.
• The sale was executed at a weighted average price of $26.0303 per share, totaling $13,882.02.
• This transaction was made under a Rule 10b5-1 trading plan adopted on December 16, 2025, intended to cover estimated tax obligations related to vested restricted stock units.
• An additional sale of 24 shares occurred on the same date at a weighted average price of $27.3254 per share.
• Following these transactions, Friedberg directly beneficially owns 81,042 shares and indirectly owns 40,000 shares through Key Recovery Group LLC and an unspecified amount through Balmoral Financial Group LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. The sale is conducted under a pre-arranged 10b5-1 plan for tax purposes, which is a common and accepted practice, rather than an opportunistic sale based on negative company outlook.

Negatives

• Director Ezra Friedberg sold a portion of his holdings in Pelthos Therapeutics Inc.

Risks

• The sale of shares by a director, even under a 10b5-1 plan, could be perceived negatively by the market, potentially impacting share price.
• The reliance on a 10b5-1 plan to cover tax obligations suggests that the director may not have sufficient liquid assets or is prioritizing tax management over holding stock.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Management Comments

• Ezra Friedberg may be deemed to beneficially own shares held by Balmoral Financial Group LLC and Key Recovery Group LLC by virtue of his managerial roles, but disclaims beneficial ownership except to the extent of his pecuniary interest.
• The reporting person undertakes to provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the Issuer, or a security holder.

Industry Context

StockSavvy.ai notes that Form 4 filings, like this one from Pelthos Therapeutics Inc., are standard disclosures for insider transactions. While sales by insiders can sometimes signal a lack of confidence, sales under a Rule 10b5-1 plan are pre-scheduled and often executed for liquidity or diversification purposes, mitigating direct interpretation of negative sentiment.

Related Party Transactions

• Ezra Friedberg is the manager of Balmoral Financial Group LLC and Key Recovery Group LLC, entities that hold shares of Pelthos Therapeutics Inc. common stock. Friedberg may be deemed to beneficially own these shares due to his managerial roles, though he disclaims beneficial ownership beyond his pecuniary interest.

Stakeholder Impact

• Shareholders: May view insider sales with caution, though the 10b5-1 plan context may temper concerns.
• Employees: The sale by a director might indirectly affect morale if perceived as a lack of confidence, but the tax-related nature of the sale may mitigate this.
• Creditors: No direct impact indicated.
• Suppliers: No direct impact indicated.
• Management: The transaction is a personal financial management action by a director.

Next Steps

• The reporting person will continue to hold shares indirectly through Balmoral Financial Group LLC and Key Recovery Group LLC, with beneficial ownership disclaimed except for pecuniary interest.
• The reporting person is obligated to provide further transaction details upon request.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Pelthos Therapeutics, Ezra Friedberg, Stock Sale, 10b5-1 Plan, Director Sale, Beneficial Ownership, Restricted Stock Units, Tax Obligations